Answers are grounded in this paper and cite their sources.
CRISPR-Cas9 engineered organoids represent the novel application of CRISPR-Cas9 genome editing technology in three-dimensional stem cell cultures, and have gained significant attention in recent years. These organoids, miniaturized 3D structures derived from stem cells, faithfully replicate the functional and structural characteristics of real organs. Their potential for disease modeling, providing insights into human development and disease mechanisms, and their ability to replicate complex organ structures and functions in vitro make organoids invaluable in medical research and drug discovery. The utilization of CRISPR-Cas9 technology enables precise genome editing of the stem cells, thereby enhancing the fidelity and accuracy of organoid models and enabling the study of mutations and diseases that were previously unable to be replicated in vitro. Recently, the integration of artificial intelligence (AI) has emerged as a promising approach to advance this technology. The convergence of CRISPR-Cas9 genome editing technology and AI can speed up and improve the CRISPR-Cas9 process for organoids by analyzing large and/or complicated datasets, predicting CRISPR-Cas9 off-target effects, improving CRISPR-Cas9 splicing accuracy, and even creating better CRISPR-Cas9 gene knockout plans. Though the technology is still at an early stage, this comprehensive review discusses the current and future utilization of AI in CRISPR-Cas9 genome editing technology for organoid creation, research, and improvement.
No takes yet. Share an insight, caveat, or question.
Zhu et al. (2024) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: